0000905718-16-001577.txt : 20160804 0000905718-16-001577.hdr.sgml : 20160804 20160804160043 ACCESSION NUMBER: 0000905718-16-001577 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160804 DATE AS OF CHANGE: 20160804 EFFECTIVENESS DATE: 20160804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dance Biopharm Holdings, Inc. CENTRAL INDEX KEY: 0001650840 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-268368 FILM NUMBER: 161807268 BUSINESS ADDRESS: STREET 1: 150 NORTH HILL DRIVE, SUITE 24 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 415-369-9415 MAIL ADDRESS: STREET 1: 150 NORTH HILL DRIVE, SUITE 24 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: Dance BioPharm Holdings, Inc. DATE OF NAME CHANGE: 20150812 D 1 primary_doc.xml X0707 D LIVE 0001650840 Dance Biopharm Holdings, Inc. 150 NORTH HILL DRIVE, SUITE 24 BRISBANE CA CALIFORNIA 94005 415-369-9415 DELAWARE SAV Holdings Corp. Dance BioPharm Holdings, Inc. Corporation true 2013 John S. Patton, Ph.D 150 North Hill Drive, Suite 24 Brisbane CA CALIFORNIA 94005 Executive Officer Director Greg S. Zante 150 North Hill Drive, Suite 24 Brisbane CA CALIFORNIA 94005 Executive Officer Lisa E. Porter, M.D. 150 North Hill Drive, Suite 24 Brisbane CA CALIFORNIA 94005 Executive Officer Vivian Yan 150 North Hill Drive, Suite 24 Brisbane CA CALIFORNIA 94005 Director Donald D. Huffman 150 North Hill Drive, Suite 24 Brisbane CA CALIFORNIA 94005 Director Adam Stern c/o Aegis Capital Corp. 810 Seventh Ave., 18th Floor New York NY NEW YORK 10019 Director Biotechnology Decline to Disclose 06b false 2016-06-20 false true true true Units consisting of common stock and warrants false 0 Aegis Capital Corp 15007 None None 810 SEVENTH AVENUE, 18TH FLOOR NEW YORK NY NEW YORK 10019 All States false 23000000 625000 22375000 Includes over-allotment option. false 2 2300000 true 0 Placement Agent is entitled to receive 10% cash and expense fees. Assumes maximum offering sold and commissions paid pursuant to over-allotment. Does not include value of warrants issuable to Placement Agent. 0 true Some of the proceeds may be used for general working capital purposes which may include payment of salaries and other fees to those listed in Item 3, as more fully set forth in the offering materials. false Dance Biopharm Holdings, Inc. /s/ John S. Patton Ph.D John S. Patton Ph.D Chief Executive Officer 2016-08-04